Article | August 18, 2022

Rethinking Cancer Treatment With Anixa's Amit Kumar

Source: Cytiva

The application of CAR T cell therapies for solid tumors has been fraught with historical obstacles – optimizing these treatments so that they reach tumors and destroy them has been difficult to reliably achieve. This is chiefly due to the gauntlet of immunosuppressive cells that protect these tumors; overcoming the hurdles that attend CAR-T therapy development will require novel science, innovative processing, and unshakeable optimism.

For Amit Kumar, PhD, chairman and CEO of Anixa Biosciences, that optimism forms the core of Anixa’s mission: advancing cancer vaccines and novel CAR T cell therapies for the treatment of breast and ovarian cancers. In a recent episode of The Business of Biotech, Dr. Kumar sat down to explain his company’s strategy to targeted cancer treatment and why Anixa’s approaches are innovative for the space.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online